Vistagen Therapeutics Files 8-K, Confirms Nasdaq Listing

Ticker: VTGN · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1411685

Vistagen Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyVistagen Therapeutics, Inc. (VTGN)
Form Type8-K
Filed DateJan 9, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, administrative

TL;DR

**Vistagen's 8-K is mostly administrative, no major news for traders.**

AI Summary

Vistagen Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on the Nasdaq Capital Market under the trading symbol VTGN. This filing, categorized as a Regulation FD Disclosure and Financial Statements and Exhibits, does not contain new material financial or operational news. For investors, this filing simply updates administrative details and reaffirms the company's compliance with SEC reporting requirements, indicating no immediate impact on stock valuation.

Why It Matters

This filing is largely administrative, confirming Vistagen's listing on the Nasdaq Capital Market. It doesn't contain new financial or operational news, so it has minimal direct impact on the stock's immediate value.

Risk Assessment

Risk Level: low — This 8-K filing is routine and administrative, disclosing no new risks or material changes to the company's operations or financial health.

Analyst Insight

Given this 8-K is purely administrative and contains no new material information, a smart investor would not make any immediate trading decisions based solely on this filing. It serves as a routine compliance update.

Key Numbers

  • $0.001 — par value per share (the par value of Vistagen's Common Stock)
  • 001-37761 — SEC File Number (Vistagen's SEC file number under the 1934 Act)
  • 650-577-3600 — business phone number (Vistagen's telephone number)

Key Players & Entities

  • Vistagen Therapeutics, Inc. (company) — the registrant filing the 8-K
  • Nasdaq Capital Market (company) — the exchange where Vistagen's common stock is registered
  • VTGN (company) — the trading symbol for Vistagen Therapeutics, Inc.
  • January 8, 2024 (date) — the date of the earliest event reported in the 8-K
  • South San Francisco, California (company) — Vistagen's principal executive offices location

FAQ

What is the primary purpose of this 8-K filing by Vistagen Therapeutics, Inc.?

The primary purpose of this 8-K filing, dated January 8, 2024, is to provide a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' items. It largely confirms administrative details about the company and its stock registration.

On which stock exchange is Vistagen Therapeutics, Inc.'s Common Stock registered?

Vistagen Therapeutics, Inc.'s Common Stock, with a par value of $0.001 per share, is registered on the Nasdaq Capital Market under the trading symbol VTGN, as stated in the filing.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024.

What is the business address and phone number for Vistagen Therapeutics, Inc. as listed in the filing?

The business address for Vistagen Therapeutics, Inc. is 343 Allerton Ave., South San Francisco, California 94090, and their telephone number is (650) 577-3600.

Does this 8-K filing indicate that Vistagen Therapeutics, Inc. is an 'emerging growth company'?

The filing includes a checkbox section to indicate whether the registrant is an emerging growth company, but none of the boxes are checked, implying the filing does not explicitly state or confirm Vistagen's status as an emerging growth company in this particular document.

Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-08 18:37:52

Key Financial Figures

  • $0.001 — ch registered Common Stock , par value $0.001 per share VTGN Nasdaq Capital Market

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits .   (d) Exhibits Index   Exhibit No.   Description 99.1   Vistagen Therapeutics, Inc. Corporate Presentation, dated January 2024. 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)        

Signatures

Signatures   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.     Vistagen Therapeutics, Inc.       Date: January 8, 2024 By: /s/ Shawn K. Singh     Shawn K. Singh Chief Executive Officer    

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.